ABT:NYE-Abbott Laboratories

EQUITY | Medical Devices | New York Stock Exchange

Last Closing Price

USD 68.79

Change

+0.29 (+0.42)%

Market Cap

USD 120.68B

Volume

5.04M

Yahoo Analyst Target

USD 71.31 (3.66%)

STA Analyst Target

USD 70.60 (2.63%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Abbott Laboratories discovers, develops, manufactures and sells health care products. Its products include branded generic pharmaceuticals manufactured internationally, marketed and sold outside the United States.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-09-20 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
MDT Medtronic plc.

+1.02 (+1.06%)

USD 131.65B
SYK Stryker Corporation

-0.04 (-0.02%)

USD 64.88B
BSX Boston Scientific Corporation

+0.33 (+0.88%)

USD 52.30B
EW Edwards Lifesciences Corporati..

+2.75 (+1.85%)

USD 31.72B
ZBH Zimmer Biomet Holdings Inc.

+0.88 (+0.68%)

USD 26.60B
SNN Smith & Nephew SNATS Inc.

+0.04 (+0.11%)

USD 16.21B
PEN Penumbra Inc.

+0.80 (+0.53%)

USD 5.20B
GMED Globus Medical Inc. Class A

+0.27 (+0.52%)

USD 5.18B
ITGR Integer Holdings Corporation

+2.60 (+3.21%)

USD 2.69B
NVRO Nevro Corp.

+0.90 (+1.54%)

USD 1.79B

ETFs Containing ABT

IHI iShares U.S. Medical Devi.. 7.99 % 0.43 %

+1.34 (+0.61%)

USD 2.98B
FTXH First Trust Nasdaq Pharma.. 7.62 % 0.60 %

+0.35 (+1.52%)

USD 5.86M
LIFE.B:CA Evolve Global Healthcare .. 5.12 % 0.67 %

N/A

CAD 1.04M
LIFE:CA Evolve Global Healthcare .. 5.12 % 0.66 %

N/A

CAD 1.46M
PJP Invesco Dynamic Pharmaceu.. 4.68 % 0.57 %

+0.84 (+1.16%)

USD 0.59B
ACT AdvisorShares Vice ETF 4.49 % 0.00 %

+0.85 (+3.21%)

USD 0.01B
PILL Direxion Daily Pharmaceut.. 3.37 % 0.00 %

+0.84 (+2.38%)

USD 5.42M
PWB Invesco Dynamic Large Cap.. 3.37 % 0.57 %

+0.24 (+0.50%)

USD 0.68B
XLV SPDR Select Sector Fund -.. 3.25 % 0.14 %

+0.91 (+0.97%)

USD 19.03B
IYH iShares U.S. Healthcare 3.04 % 0.43 %

+1.82 (+0.91%)

USD 2.32B
VHT Vanguard Health Care 2.75 % 0.10 %

+1.60 (+0.90%)

USD 8.83B
FHLC Fidelity MSCI Health Care.. 2.74 % 0.08 %

+0.44 (+0.96%)

USD 1.47B
VIG Vanguard Div Appreciation 2.44 % 0.08 %

+0.72 (+0.65%)

USD 30.93B
CCOR Cambria Core Equity 2.33 % 1.21 %

-0.01 (-0.04%)

USD 0.08B
IXJ iShares Global Healthcare 2.28 % 0.47 %

+0.64 (+1.03%)

USD 1.76B
JHMH John Hancock Multifactor .. 1.98 % 0.50 %

+0.35 (+1.00%)

USD 0.06B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.54% 46% F 88% B+
Dividend Return 1.47% 100% A+ 34% F
Total Return 22.01% 54% F 88% B+
Trailing 12 Months  
Capital Gain 32.57% 62% D- 88% B+
Dividend Return 2.13% 83% B 33% F
Total Return 34.70% 62% D- 89% B+
Trailing 5 Years  
Capital Gain 94.93% 36% F 87% B+
Dividend Return 13.94% 71% C- 46% F
Total Return 108.87% 36% F 88% B+
Average Annual (5 Year Horizon)  
Capital Gain 12.95% 31% F 82% B-
Dividend Return 15.31% 31% F 83% B
Total Return 2.36% 86% B 45% F
Risk Return Profile  
Volatility (Standard Deviation) 18.99% 69% D+ 38% F
Risk Adjusted Return 80.59% 46% F 68% D+
Market Capitalization 56.45B 93% A 98% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.70 14% F 4% F
Price/Book Ratio 3.84 64% D 21% F
Price / Cash Flow Ratio 4.97 50% F 26% F
Price/Free Cash Flow Ratio 24.92 57% F 27% F
Management Effectiveness  
Return on Equity 2.97% 36% F 31% F
Return on Invested Capital 5.53% 43% F 35% F
Return on Assets 1.29% 36% F 37% F
Debt to Equity Ratio 75.75% 42% F 49% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.

ABT:NYE-Abbott Laboratories

EQUITY | Medical Devices | New York Stock Exchange

Last Closing Price

USD 68.79

Change

+0.29 (+0.42)%

Market Cap

USD 120.68B

Volume

5.04M

Yahoo Analyst Target

USD 71.31 (3.66%)

STA Analyst Target

USD 70.60 (2.63%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-09-20